Details

Autor(en) / Beteiligte

• Harwood, Rachel
• Allin, Benjamin
• Jones, Christine E
• Whittaker, Elizabeth
• Ramnarayan, Padmanabhan
• Ramanan, Athimalaipet V
• Kaleem, Musa
• Tulloh, Robert
• Peters, Mark J
• Almond, Sarah
• Davis, Peter J
• Levin, Michael
• Tometzki, Andrew
• Faust, Saul N
• Knight, Marian
• Kenny, Simon
• Agbeko, Rachel
• Aragon, Octavio
• Baird, Jim
• Bamford, Alasdair
• Bereford, Michael
• Bharucha, Tara
• Brogan, Paul
• Butler, Karina
• Carroll, Enitan
• Cathie, Katrina
• Chikermane, Ashish
• Christie, Sharon
• Clark, Matthew
• Deri, Antigoni
• Doherty, Conor
• Drysdale, Simon
• Duong, Phouc
• Durairaj, Saravanan
• Emonts, Marieke
• Evans, Jennifer
• Fraser, James
• Hackett, Scott
• Hague, Rosie
• Heath, Paul
• Herberg, Jethro
• Ilina, Marina
• Jay, Nicola
• Kelly, Dominic
• Kerrison, Caroline
• Kraft, Jeannette
• Leahy, Alice
• Linney, Mike
• Lyall, Hermione
• McCann, Liza
• McMaster, Paddy
• Miller, Owen
• O'Riordan, Sean
• Owens, Stephen
• Pain, Clare
• Patel, Sanjay
• Pathan, Nazima
• Pauling, James
• Porter, David
• Prendergast, Andrew
• Ravi, Kumar
• Riorden, Andrew
• Roderick, Marion
• Scholefield, Barnaby R
• Semple, Malcolm G
• Sen, Ethan
• Shackley, Fiona
• Sinha, Ian
• Tibby, Shane
• Verganano, Stefania
• Welch, Steven B
• Wilkinson, Nicholas
• Wood, Mark
• Yardley, Iain

Titel

A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process

Ist Teil von

• The lancet child & adolescent health, 2021-02, Vol.5 (2), p.133-141

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2021

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS) is a novel condition that was first reported in April, 2020. We aimed to develop a national consensus management pathway for the UK to provide guidance for clinicians caring for children with PIMS-TS. A three-phase online Delphi process and virtual consensus meeting sought consensus over the investigation, management, and research priorities from multidisciplinary clinicians caring for children with PIMS-TS. We used 140 consensus statements to derive a consensus management pathway that describes the initial investigation of children with suspected PIMS-TS, including blood markers to help determine the severity of disease, an echocardiogram, and a viral and septic screen to exclude other infectious causes of illness. The importance of a multidisciplinary team in decision making for children with PIMS-TS is highlighted throughout the guidance, along with the recommended treatment options, including supportive care, intravenous immunoglobulin, methylprednisolone, and biological therapies. These include IL-1 antagonists (eg, anakinra), IL-6 receptor blockers (eg, tocilizumab), and anti-TNF agents (eg, infliximab) for children with Kawasaki disease-like phenotype and non-specific presentations. Use of a rapid online Delphi process has made it possible to generate a national consensus pathway in a timely and cost-efficient manner in the middle of a global pandemic. The consensus statements represent the views of UK clinicians and are applicable to children in the UK suspected of having PIMS-TS. Future evidence will inform updates to this guidance, which in the interim provides a solid framework to support clinicians caring for children with PIMS-TS. This process has directly informed new PIMS-TS specific treatment groups as part of the adaptive UK RECOVERY trial protocol, which is the first formal randomised controlled trial of therapies for PIMS-TS globally.